{"protocolSection":{"identificationModule":{"nctId":"NCT06477783","orgStudyIdInfo":{"id":"64007957MMY4010"},"organization":{"fullName":"Universitaire Ziekenhuizen KU Leuven","class":"OTHER"},"briefTitle":"Study on the Clinical Efficacy of Teclistamab","officialTitle":"Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium","acronym":"TECTONIC"},"statusModule":{"statusVerifiedDate":"2024-03","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-09","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2027-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-05-14","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-06-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Universitaire Ziekenhuizen KU Leuven","class":"OTHER"},"collaborators":[{"name":"Janssen Pharmaceutica","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The aim of this study is to assess the clinical efficacy and safety of the anti-BCMA/CD3 bispecific antibody teclistamab (Tecvayli®) in a prospective, real-life setting in Belgium.","detailedDescription":"To assess the clinical efficacy and safety of teclistamab (Tecvayli®) in relapsed/refractory multiple myeloma patients who have received at least 3 prior lines of treatment and who will receive teclistamab (Tecvayli®) as the next treatment. Patients will be followed up prospectively until the end of study (24 months/2 years), or until disease progression, withdrawal of consent death or loss to follow-up, whichever occurs first. Each patient will have a monthly follow-up from baseline until 6 months of treatment with teclistamab. Then, data will be collected every 3 months until the end of study."},"conditionsModule":{"conditions":["Multiple Myeloma","Hematologic Diseases"],"keywords":["Teclistamab","Tecvayli","Hematology","Efficacy","Safety"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Relapsed or refractory multiple myeloma patients","description":"Patients aged 18 years or older diagnosed with relapsed or refractory multiple myeloma, who received at least 3 prior lines of treatment. They should be refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody. After confirmation of disease progression, the patients will start treatment with teclistamab per routine clinical care or will have started with teclistamab treatment ≤14 days before intended screening visit","interventionNames":["Drug: Teclistamab"]}],"interventions":[{"type":"DRUG","name":"Teclistamab","description":"Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.","armGroupLabels":["Relapsed or refractory multiple myeloma patients"],"otherNames":["Tecvayli"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall response rate","description":"The primary objective is the overall response rate (partial response (PR) or better) according to the 2016 IMWG response criteria of Multiple myeloma.","timeFrame":"At baseline, monthly until end of study (maximum 24 months)"}],"secondaryOutcomes":[{"measure":"Progression-free survival (PFS)","description":"The length of time during and after the treatment during which a patient lives with the disease but it does not get worse.","timeFrame":"At baseline, monthly until end of study (maximum 24 months)"},{"measure":"Overall survival (OS)","description":"Duration of time between start of the treatment and up to the time of death.","timeFrame":"At baseline, monthly until end of study (maximum 24 months)"},{"measure":"Incidence of (serious) adverse events","description":"Incidence and severity of (serious) adverse events with with focus on hematological AE's (≥ grade 3), cytokine release syndrome (CRS) rate, Immune effector cell-associated neurotoxicity syndrome (ICANS) and infections (≥ grade 2) and serious adverse events related to teclistamab (Tecvayli®).","timeFrame":"At baseline, monthly until end of study (maximum 24 months)"},{"measure":"Depth of response","description":"Evaluation of response in terms of depth. Assessment of response according to the 2016 IMWG response criteria of Multiple myeloma.","timeFrame":"At baseline, monthly until end of study (maximum 24 months)"},{"measure":"Time to response (TTR)","description":"Assessment of the time it takes for a patient to achieve partial response (PR) or better.","timeFrame":"At baseline, monthly until end of study (maximum 24 months)"},{"measure":"Duration of response","description":"Assessment of the length of time during which a patient experiences a partial response (PR) or better. It is measure from the start of treatment until disease progression or death.","timeFrame":"At baseline, monthly until end of study (maximum 24 months)"},{"measure":"Minimal Residual Disease (MRD) assessment","description":"Evaluation of treatment efficacy by monitoring for the presence of a small number of cancer cells that are left in the body. MRD assessment will be done with Next Gen Flow (NGF) or Next Gen Sequencing (NGS).","timeFrame":"At suspected CR, every 6 months thereafter until end of study (maximum 24 months)"},{"measure":"Time to next treatment (TTNT)","description":"Assessment of the time interval between initiation of treatment with Tecvayli® and commencement of the next line of therapy.","timeFrame":"At baseline, monthly until end of study (maximum 24 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age 18 years or older\n* written informed consent\n* has a diagnosis of relapsed and refractory multiple myeloma\n* received at least three prior lines of therapy\n* is refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody\n* evidence of disease progression on the last line of therapy, based on determination of response by the IMWG response criteria\n* anticipated to start treatment with teclistamab per routine clinical care or has started with teclistamab treatment ≤14 days before intended screening visit\n\nExclusion Criteria:\n\n* Has participated in a teclistamab trial (teclistamab or control arm) or teclistamab Single Patient Request (SPR) program\n* Has started teclistamab treatment \\>14 days before intended screening visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"100 patients with relapsed or refractory multiple myelome who will be treated with teclistamab (Tecvayli®)","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Michel Delforge, MD, PhD","role":"CONTACT","phone":"+32 16 34 68 80","email":"michel.delforge@uzleuven.be"}],"overallOfficials":[{"name":"Michel Delforge, MD, PhD","affiliation":"UZ Leuven Gasthuisberg","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"UZ Leuven Gasthuisberg","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000009101","term":"Multiple Myeloma"},{"id":"D000054219","term":"Neoplasms, Plasma Cell"},{"id":"D000006402","term":"Hematologic Diseases"}],"ancestors":[{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000020141","term":"Hemostatic Disorders"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010265","term":"Paraproteinemias"},{"id":"D000001796","term":"Blood Protein Disorders"},{"id":"D000006474","term":"Hemorrhagic Disorders"},{"id":"D000008232","term":"Lymphoproliferative Disorders"},{"id":"D000007160","term":"Immunoproliferative Disorders"},{"id":"D000007154","term":"Immune System Diseases"}],"browseLeaves":[{"id":"M12058","name":"Multiple Myeloma","asFound":"Multiple Myeloma","relevance":"HIGH"},{"id":"M27588","name":"Neoplasms, Plasma Cell","asFound":"Multiple Myeloma","relevance":"HIGH"},{"id":"M9490","name":"Hematologic Diseases","asFound":"Hematologic Diseases","relevance":"HIGH"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M21977","name":"Hemostatic Disorders","relevance":"LOW"},{"id":"M5059","name":"Blood Coagulation Disorders","relevance":"LOW"},{"id":"M17400","name":"Vascular Diseases","relevance":"LOW"},{"id":"M13178","name":"Paraproteinemias","relevance":"LOW"},{"id":"M5077","name":"Blood Protein Disorders","relevance":"LOW"},{"id":"M9560","name":"Hemorrhagic Disorders","relevance":"LOW"},{"id":"M11225","name":"Lymphoproliferative Disorders","relevance":"LOW"},{"id":"M10206","name":"Immunoproliferative Disorders","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"T3947","name":"Multiple Myeloma","asFound":"Multiple Myeloma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M4230","name":"Antibodies, Monoclonal","relevance":"LOW"},{"id":"M4225","name":"Antibodies","relevance":"LOW"},{"id":"M10184","name":"Immunoglobulins","relevance":"LOW"},{"id":"M2853","name":"Immunomodulating Agents","relevance":"LOW"},{"id":"M272211","name":"Daratumumab","relevance":"LOW"},{"id":"M29889","name":"Proteasome Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"ANeo","name":"Antineoplastic Agents"}]}},"hasResults":false}